Abbott Laboratories Corporation

Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Abbott Gmbh & Co Kg

Gerard B Fox

Chung-Ming Hsieh

Ulrich Ebert

Jijie Gu

Martin Schmidt

Reinhold Mueller

Volker Nimmrich

Enrico L Digiammarino

John E Harlan

Ralf Loebbert

Zhen Wu

Feng Luo

Marlon D Cowart

Kaitlin E Browman

Lynne E Rueter

Jorge D Brioni

Timothy A Esbenshade

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

The invention relates to a method of administering histamine Hantagonist and an antipsychotic therapeutic agent, compositions comprising a histamine Hantagonist and an antipsychotic therapeutic agent, and a related article of manufacture.

Treatment of schizophrenia and related disorders

Growing community of inventors

Barrington Hills, IL, United States of America

Gerard B Fox